The present report focuses on the various aspects of oral delivery of anticancer drugs. The
significance of oral delivery in cancer therapeutics has been highlighted which principally …

Introduction: Many therapeutics are limited to parenteral administration. Oral administration
is a desirable alternative because of the convenience and increased compliance by …

Background Few options exist for treatment of patients with small-cell lung cancer (SCLC)
after failure of first-line therapy. Lurbinectedin is a selective inhibitor of oncogenic …

Purpose Amrubicin, a third-generation anthracycline and potent topoisomerase II inhibitor,
showed promising activity in small-cell lung cancer (SCLC) in phase II trials. This phase III …

Background Small cell lung cancer (SCLC) is a lethal disease for which there have been
only small advances in diagnosis and treatment in the past decade. Our goal was to revise …

Purpose For patients with small-cell lung cancer (SCLC), further chemotherapy is routinely
considered at relapse after first-line therapy. However, proof of clinical benefit has not been …

Purpose Single-agent intravenous (IV) topotecan is an effective treatment for small-cell lung
cancer (SCLC) after failure of first-line chemotherapy. This open-label, randomized, phase III …

Supported by detailed understanding of their mechanism of action, and facilitated by
chemical manipulations that have amplified their solubility, the camptothecins have …

Oncology is one of the few areas of medicine where most patients are treated intravenously
rather than receiving oral drugs. Recently, several oral anti-cancer drugs have been …

Small cell lung cancer (SCLC) is an aggressive lung tumour strongly associated with
cigarette smoking, with patients often presenting with metastatic disease at the time of …